who classification of tumours of the urinary syst
hromophobe RCC: Chromosomal losses, mitochondrial abnormalities. Urothelial carcinoma: FGFR3 mutations, TP53 alterations. Incorporating molecular data improves prognostication and opens avenues for targeted therapies. Practical Approach